GLP-1 receptor agonists (such as semaglutide) offer a groundbreaking approach by targeting the brain's mesolimbic reward center: the area responsible for the dopamine "high" and subsequent cravings
This receptor profile interferes with hypothalamic appetite regulation, reduces energy expenditure, and impairs peripheral insulin signaling
instead, it creates a gradual reduction in hunger signals that compounds over consecutive days
Omega-3 Fatty Acids Omega-3 fatty acids, particularly the long-chain fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), support numerous physiological functions in the body, including the regulation of inflammation, modulation of immune function and support of cardiovascular health
However, the risk of developing thyroid cancer was 1.85 times higher within the first year after initiating GLP-1 RA treatment compared with the other three drugs